Table 1.
Demographic and clinical characteristics of patients with Hurthle cell carcinoma
| Variable | Number | Percent |
|---|---|---|
| Gender | ||
| Female | 187 | 78.2 |
| Males | 52 | 21,8 |
| Age | 54,3 ± 13,7 | |
| 20–29 | 10 | 4,2 |
| 30–39 | 28 | 11,7 |
| 40–49 | 46 | 19,2 |
| 50–59 | 66 | 27,6 |
| 60–69 | 53 | 22,2 |
| > 70 | 36 | 15,1 |
| pT tumor stage | ||
| T1 | 19 | 7,9 |
| T2 | 112 | 46,9 |
| T3 | 75 | 31,4 |
| T4 | 33 | 13,8 |
| N stage | ||
| N0 | 72 | 30,1 |
| N1a | 5 | 2,1 |
| N1b | 1 | 0,4 |
| Nx | 161 | 67,4 |
| Tumor invasiveness | ||
| minimally invasive | 102 | 67,1 |
| widely invasive | 50 | 32,9 |
| Tumor size (mm) | ||
| <39 | 93 | 46 |
| ≥40 | 109 | 54 |
| Capsular invasion | ||
| transcapsular | 152 | 69,7 |
| no or minimal | 66 | 30,3 |
| Vascular invasion | ||
| positive | 146 | 67 |
| no or minimal | 72 | 33 |
| Number of tumor focuses | ||
| one focus | 167 | 76,6 |
| multicentric | 51 | 21,3 |
| Regional tumor infiltration | ||
| positive | 33 | 13,8 |
| negative | 206 | 86,2 |
| Thyroglobulin | ||
| normal values (<68 ng/mL) | 19 | 26,8 |
| elevated values (>68 ng/mL) | 52 | 73,2 |
| Radioiodine ablation after surgery | ||
| Yes | 65 | 36,9 |
| No | 111 | 63,1 |
| Surgeon experience | ||
| resident | 11 | 4,6 |
| specialist 1–5 years | 20 | 8,4 |
| specialist 6–10 years | 57 | 23,8 |
| specialist over 10 years | 151 | 63,2 |